In the past decade, IL-27 has attracted considerable interest as a potent antitumor cytokine via CD8+ T cell-dependent tumor rejection [25], limiting the inducible Treg (iTreg) or Treg population [26, 27], enhancing NK cell response [28], and inhibiting angiogenesis and tumor cell proliferation [7, 29]. This evidence concerns the gene CD8A and neoplasm.